annovis bio, inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. its lead compound is anvs401, which is in phase 2a clinical trials for the treatment of alzheimer's disease (ad), parkinson's disease, alzheimer's disease in down syndrome, and other chronic neurodegenerative disorders. the company is also developing anvs405 for protecting the brain after traumatic brain injury and/or stroke; and anvs301, which is in phase i clinical trials to increase cognitive capability in later stages of ad and dementia. annovis bio, inc. was founded in 2008 and is based in berwyn, pennsylvania.
Company profile
Ticker
ANVS
Exchange
Website
CEO
Maria Maccecchini
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
QR Pharma, Inc.
SEC CIK
Corporate docs
IRS number
262540421
ANVS stock data
Latest filings (excl ownership)
8-K
Other Events
22 Mar 24
8-K
Entry into a Material Definitive Agreement
21 Mar 24
8-K
Annovis Bio Provides Data Announcement Update for the Phase Ii/iii Study of Buntanetap In Alzheimer’s Disease
20 Mar 24
8-K
Other Events
19 Mar 24
424B5
Prospectus supplement for primary offering
18 Mar 24
424B5
Prospectus supplement for primary offering
18 Mar 24
8-K
Entry into a Material Definitive Agreement
15 Mar 24
EFFECT
Notice of effectiveness
13 Feb 24
S-3/A
Shelf registration (amended)
12 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
Latest ownership filings
SC 13G/A
HIRSCHMAN ORIN
28 Nov 23
4/A
Mark K. White
22 Nov 23
4/A
Reid McCarthy
22 Nov 23
4/A
Michael B Hoffman
22 Nov 23
4/A
Maria-Luisa Maccecchini
22 Nov 23
4/A
Henry Hagopian III
22 Nov 23
4/A
Claudine Bruck
22 Nov 23
4
Reid McCarthy
21 Nov 23
4
Michael B Hoffman
21 Nov 23
4
Mark K. White
21 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.35 mm | 6.35 mm | 6.35 mm | 6.35 mm | 6.35 mm | 6.35 mm |
Cash burn (monthly) | 3.12 mm | 2.14 mm | 4.95 mm | 3.53 mm | 3.12 mm | 2.85 mm |
Cash used (since last report) | 18.60 mm | 12.72 mm | 29.51 mm | 21.04 mm | 18.60 mm | 16.98 mm |
Cash remaining | -12.25 mm | -6.37 mm | -23.16 mm | -14.69 mm | -12.25 mm | -10.63 mm |
Runway (months of cash) | -3.9 | -3.0 | -4.7 | -4.2 | -3.9 | -3.7 |
Institutional ownership, Q3 2023
13.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 30 |
Opened positions | 3 |
Closed positions | 1 |
Increased positions | 6 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 10.54 bn |
Total shares | 1.41 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Adage Capital Partners GP, L.L.C. | 300.00 k | $2.85 bn |
Hirschman Orin | 293.36 k | $2.98 mm |
Vanguard | 258.53 k | $2.45 bn |
BLK Blackrock | 96.28 k | $913.71 mm |
Geode Capital Management | 56.04 k | $531.98 mm |
AIGH Capital Management | 48.94 k | $464.45 mm |
Wescott Financial Advisory | 41.61 k | $394.85 mm |
Merit Financial | 41.20 k | $390.99 mm |
Sterling Investment Advisors | 34.37 k | $326.21 mm |
Redmond Asset Management | 34.08 k | $323.42 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Nov 23 | Henry Hagopian III | Common Stock | Grant | Acquire A | No | No | 6.1 | 820 | 5.00 k | 1,820 |
20 Nov 23 | Bruck Claudine | Common Stock | Other | Acquire J | No | No | 0 | 0 | 0.00 | 6,567 |
20 Nov 23 | Hoffman Michael B | Common Stock | Grant | Acquire A | Yes | No | 6.1 | 163,880 | 999.67 k | 223,357 |
20 Nov 23 | Reid McCarthy | Common Stock | Other | Acquire J | No | No | 0 | 0 | 0.00 | 7,305 |
20 Nov 23 | Maccecchini Maria-Luisa | Common Stock | Grant | Acquire A | No | No | 6.1 | 40,970 | 249.92 k | 1,098,459 |
News
HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target
21 Mar 24
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
20 Mar 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
20 Mar 24
Sportradar Group Posts Upbeat Earnings, Joins Kingsoft Cloud, Braskem And Other Big Stocks Moving Higher On Wednesday
20 Mar 24
Brookline Capital Downgrades Annovis Bio to Hold, Announces $9 Price Target
28 Feb 24